Loring Wolcott & Coolidge Fiduciary Advisors LLP Novavax Inc Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.5 Billion
- Q2 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Novavax Inc stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 570 shares of NVAX stock, worth $9,752. This represents 0.0% of its overall portfolio holdings.
Number of Shares
570
Previous 570
-0.0%
Holding current value
$9,752
Previous $2,000
250.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NVAX
# of Institutions
247Shares Held
76MCall Options Held
5.06MPut Options Held
7.19M-
State Street Corp Boston, MA16.9MShares$289 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.5MShares$231 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.43MShares$161 Million0.0% of portfolio
-
Shah Capital Management8.12MShares$139 Million19.75% of portfolio
-
Geode Capital Management, LLC Boston, MA2.59MShares$44.3 Million0.0% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $1.34B
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...